Citizens Jmp Issues Positive Forecast for Cytokinetics (NASDAQ:CYTK) Stock Price

Cytokinetics (NASDAQ:CYTK) had its price objective hoisted by Citizens Jmp from $105.00 to $110.00 in a research report sent to investors on Friday morning,Benzinga reports. They currently have a market outperform rating on the biopharmaceutical company’s stock.

Several other equities research analysts have also recently commented on the company. JPMorgan Chase & Co. upped their price target on Cytokinetics from $92.00 to $97.00 and gave the stock an “overweight” rating in a research note on Tuesday, May 12th. HC Wainwright boosted their price objective on shares of Cytokinetics from $136.00 to $140.00 and gave the company a “buy” rating in a research note on Monday, May 11th. UBS Group upgraded shares of Cytokinetics from a “neutral” rating to a “buy” rating and upped their price objective for the stock from $69.00 to $115.00 in a research report on Monday, June 29th. Weiss Ratings restated a “sell (d-)” rating on shares of Cytokinetics in a research note on Friday, July 17th. Finally, Truist Financial set a $106.00 price target on shares of Cytokinetics in a research note on Tuesday, May 5th. One research analyst has rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $100.85.

Cytokinetics Stock Down 5.7%

Shares of NASDAQ CYTK opened at $76.76 on Friday. The business has a 50-day moving average price of $78.91 and a 200 day moving average price of $70.90. The stock has a market cap of $9.55 billion, a PE ratio of -10.63 and a beta of 0.38. Cytokinetics has a 52-week low of $32.89 and a 52-week high of $88.31.

Cytokinetics (NASDAQ:CYTK) last issued its quarterly earnings data on Thursday, August 6th. The biopharmaceutical company reported ($1.50) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.63) by $0.13. The business had revenue of $28.62 million for the quarter, compared to analysts’ expectations of $17.59 million. During the same period in the previous year, the business posted ($1.12) earnings per share. The company’s revenue for the quarter was down 57.1% on a year-over-year basis. Sell-side analysts anticipate that Cytokinetics will post -6.2 earnings per share for the current year.

Insiders Place Their Bets

In other Cytokinetics news, Director B Lynne Parshall sold 5,000 shares of the firm’s stock in a transaction on Monday, June 1st. The stock was sold at an average price of $74.08, for a total value of $370,400.00. Following the completion of the sale, the director owned 15,784 shares of the company’s stock, valued at approximately $1,169,278.72. This trade represents a 24.06% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Robert I. Blum sold 7,500 shares of the business’s stock in a transaction on Wednesday, July 1st. The stock was sold at an average price of $84.92, for a total transaction of $636,900.00. Following the sale, the chief executive officer owned 377,830 shares in the company, valued at $32,085,323.60. The trade was a 1.95% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders sold 115,179 shares of company stock worth $9,126,054. 2.60% of the stock is owned by corporate insiders.

Institutional Trading of Cytokinetics

A number of institutional investors have recently added to or reduced their stakes in the stock. EverSource Wealth Advisors LLC grew its position in Cytokinetics by 723.7% during the second quarter. EverSource Wealth Advisors LLC now owns 766 shares of the biopharmaceutical company’s stock worth $25,000 after buying an additional 673 shares during the period. Kemnay Advisory Services Inc. purchased a new position in Cytokinetics in the fourth quarter valued at about $27,000. Kestra Advisory Services LLC acquired a new stake in shares of Cytokinetics during the 4th quarter valued at approximately $29,000. Quarry LP acquired a new stake in shares of Cytokinetics during the 3rd quarter valued at approximately $30,000. Finally, TD Waterhouse Canada Inc. purchased a new stake in shares of Cytokinetics during the 4th quarter worth approximately $32,000.

Key Cytokinetics News

Here are the key news stories impacting Cytokinetics this week:

• Positive Sentiment: Myqorzo uptake is encouraging. Management and analysts highlighted strong early traction for Myqorzo, supporting the view that the drug could become an important commercial growth driver. CYTK Q2 Earnings Top Estimates, Myqorzo Uptake Strong
• Positive Sentiment: Quarterly results exceeded expectations. Cytokinetics reported revenue of $28.6 million versus consensus estimates near $17.6 million and a loss of $1.50 per share, narrower than the expected $1.63 loss. Cytokinetics Reports Second Quarter 2026 Financial Results and Provides Business Update
• Positive Sentiment: Analysts raised their targets. Needham increased its target from $102 to $112 and maintained a “buy” rating, while Citizens JMP raised its target from $105 to $110 and kept a “market outperform” rating. These actions indicate analysts see meaningful upside if the launch continues to perform. Analyst Price Target Updates
• Neutral Sentiment: The commercial launch is still early. RBC viewed the earnings beat as supportive of Myqorzo’s launch, but investors will likely focus on prescription growth, reimbursement and the pace at which sales offset launch expenses.
• Negative Sentiment: Profitability and cash flow remain major concerns. Revenue fell 57.1% year over year, while Cytokinetics posted a $179.2 million operating loss and used $159.8 million in operating cash during the quarter. Higher launch costs and the absence of milestone payments also weighed on results, despite the $1.17 billion cash balance. Cytokinetics Q2 2026 Earnings: Revenue Beats but Losses Persist
• Negative Sentiment: Reported losses widened from the prior-year quarter. The quarterly loss increased from $1.12 per share a year earlier to $1.50, underscoring that CYTK remains dependent on successful commercialization and future financing or milestone opportunities. Cytokinetics Reports Q2 Loss, Beats Revenue Estimates

Cytokinetics Company Profile

Cytokinetics, Inc is a late‐stage biopharmaceutical company focused on the discovery and development of novel small‐molecule therapeutics that modulate muscle function. Founded in 1998 and headquartered in South San Francisco, California, the company applies its proprietary insights in muscle biology to address diseases characterized by impaired muscle performance. Its research spans both cardiac and skeletal muscle targets, aiming to deliver innovative medicines for conditions with significant unmet medical need.

The company’s most advanced program, omecamtiv mecarbil, is being evaluated for the treatment of heart failure by enhancing cardiac muscle contractility.